LaNova Medicines

LaNova Medicines, based in Shanghai, China, is a biotechnology company. In July 2025 Sino Biopharmaceutical bought the 95.09 per cent of LaNova it did not already own, for a total consideration of about USD 951 million, making it an indirect wholly owned subsidiary; LaNova had earlier licensed its PD-1 and VEGF bispecific antibody LM-299 to MSD and its GPRC5D antibody-drug conjugate LM-305 to AstraZeneca. LaNova Medicines is a clinical-stage biopharmaceutical company developing monoclonal antibodies, antibody-drug conjugates and bispecific antibodies for tumour immunology and the tumour microenvironment. On ClinicalTrials.gov it is the lead sponsor of 10 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing LM-168, LM-108, LM-299, LM101 and LM-350 in gastric & gastro-oesophageal junction cancer. The largest, NCT07362186 (LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma), plans to enrol 400 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.